| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Cefoxitin sodium exerts its antibacterial activity by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefoxitin is a cephamycin antibiotic that is highly resistant to β-lactamase inactivation.
|
|---|---|
| ln Vitro |
Cefoxitin sodium is a broad-spectrum antibiotic effective against a range of bacteria. It shows bactericidal activity against Bacteroides, Gram-negative bacteria, including strains of Proteus mirabilis. The compound is resistant to many β-lactamases, providing enhanced activity against certain resistant organisms. It is commonly used in the treatment of infections, including intra-abdominal infections and respiratory tract infections.
|
| ln Vivo |
Cefoxitin sodium is commonly used in the treatment of infections, including intra-abdominal infections and respiratory tract infections. As a beta-lactam antibiotic, it works by inhibiting bacterial cell wall synthesis, leading to cell death. The compound is resistant to many β-lactamases, providing enhanced activity against certain resistant organisms. It is a semisynthetic cephamycin antibiotic derived from Cephamycin C.
|
| Enzyme Assay |
Cefoxitin sodium's activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs) can be evaluated using competitive binding assays with radiolabeled penicillin. The compound's stability against β-lactamase enzymes can be evaluated using standard β-lactamase inhibition assays.
|
| Cell Assay |
Cellular assays for cefoxitin sodium are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units. The compound's bactericidal activity against Bacteroides and Gram-negative bacteria can be evaluated.
|
| Animal Protocol |
In vivo animal model experiments for cefoxitin sodium would involve administration to animal models of infection to evaluate its efficacy. Studies may include models of intra-abdominal infections and respiratory tract infections. The compound's resistance to β-lactamase enzymes makes it particularly useful for studying resistant infections. Such studies are essential for understanding the compound's in vivo behavior and therapeutic potential.
|
| ADME/Pharmacokinetics |
Cefoxitin sodium is a beta-lactam, second-generation cephalosporin antibiotic. Specific pharmacokinetic data is not extensively detailed in the available literature. As a cephamycin antibiotic, it is expected to have good tissue distribution and renal excretion. The compound is administered parenterally.
|
| Toxicity/Toxicokinetics |
Cefoxitin sodium is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Cefoxitin sodium is an organic molecular entity. Cefoxitin sodium is the sodium salt form of cefoxitin, a second-generation cephalosporin antibiotic of the β-lactam class with bactericidal activity. Cefoxitin sodium binds to and inactivates penicillin-binding protein (PBP) located on the inner membrane of bacterial cell walls. PBP is involved in the final stages of bacterial cell wall assembly and cell wall remodeling during cell division. Inactivation of PBP interferes with the cross-linking of peptidoglycan chains, which is essential for maintaining the strength and rigidity of bacterial cell walls. This leads to weakening of the bacterial cell wall and ultimately cell lysis. A semi-synthetic cephalosporin antibiotic resistant to β-lactamases. See also: Cefoxitin (with active fraction).
Cefoxitin Sodium (CAS# 33564-30-6) is the sodium salt form of cefoxitin, a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. It is a semisynthetic cephamycin antibiotic derived from Cephamycin C and is highly resistant to β-lactamase inactivation. Cefoxitin sodium binds to and inactivates penicillin-binding proteins (PBPs), interfering with peptidoglycan cross-linking. It is commonly used in the treatment of intra-abdominal infections and respiratory tract infections. |
| Molecular Formula |
C16H16N3NAO7S2
|
|---|---|
| Molecular Weight |
449.43
|
| Exact Mass |
449.032
|
| CAS # |
33564-30-6
|
| Related CAS # |
Cefoxitin;35607-66-0
|
| PubChem CID |
23667300
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
843.4ºC at 760 mmHg
|
| Melting Point |
>160°C
|
| Flash Point |
463.9ºC
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
750
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3=CC=CS3.[Na+]
|
| InChi Key |
GNWUOVJNSFPWDD-XMZRARIVSA-M
|
| InChi Code |
InChI=1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1
|
| Chemical Name |
sodium;(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
Cenomycin; Cefoxitin sodium salt; Cefoxitin Sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~222.50 mM)
H2O : ≥ 100 mg/mL (~222.50 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (111.25 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2250 mL | 11.1252 mL | 22.2504 mL | |
| 5 mM | 0.4450 mL | 2.2250 mL | 4.4501 mL | |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.2250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
